Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Novo Nordisk A/S ADR (NVO)
Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 434,438,016
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 25,057 M
  • Annual Income, $ 7,862 M
  • 60-Month Beta 0.40
  • Price/Sales 17.48
  • Price/Cash Flow 50.63
  • Price/Book 32.93
Trade NVO with:

Options Overview Details

View History
  • Implied Volatility 27.15% ( -1.09%)
  • Historical Volatility 28.48%
  • IV Percentile 56%
  • IV Rank 26.19%
  • IV High 44.88% on 08/03/23
  • IV Low 20.86% on 03/06/23
  • Put/Call Vol Ratio 0.48
  • Today's Volume 15,571
  • Volume Avg (30-Day) 19,023
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 216,828
  • Open Int (30-Day) 217,571

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.66
  • Number of Estimates 4
  • High Estimate 0.69
  • Low Estimate 0.62
  • Prior Year 0.41
  • Growth Rate Est. (year over year) +60.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
95.74 +0.94%
on 12/07/23
105.69 -8.56%
on 11/24/23
-5.12 (-5.03%)
since 11/08/23
3-Month
86.96 +11.13%
on 10/03/23
105.69 -8.56%
on 11/24/23
-1.06 (-1.08%)
since 09/08/23
52-Week
64.44 +49.96%
on 12/09/22
105.69 -8.56%
on 11/24/23
+32.74 (+51.25%)
since 12/08/22

Most Recent Stories

More News
Why Viking Therapeutics Was Crushing It This Week

Nowadays, it's good to be a developer of next-generation weight loss drugs.

NVO : 96.64 (-0.18%)
VKTX : 18.48 (+2.44%)
RHHBY : 36.0000 (+1.18%)
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?

These drugs address a rapidly growing market.

NVO : 96.64 (-0.18%)
LLY : 598.05 (+1.66%)
1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague

Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a historically cheap outperformer, as well as an industry leader that could struggle...

NVDA : 475.06 (+1.95%)
AMZN : 147.42 (+0.37%)
DXCM : 116.97 (-1.61%)
SHOP : 72.52 (+0.92%)
GOOGL : 134.99 (-1.42%)
GOOG : 136.64 (-1.31%)
TSLA : 243.84 (+0.49%)
PANW : 298.42 (+1.64%)
MNST : 53.92 (-0.70%)
NVO : 96.64 (-0.18%)
3 No-Brainer Growth Stocks to Buy in December

No analysis paralysis is required with these great stocks.

NKE : 115.91 (+0.96%)
LLY : 598.05 (+1.66%)
NVO : 96.64 (-0.18%)
VRTX : 350.15 (-1.07%)
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?

This company famously helps manage a prevalent chronic illness.

LLY : 598.05 (+1.66%)
PFE : 28.78 (+0.52%)
NVO : 96.64 (-0.18%)
An Important History Lesson for Gene-Editing Investors

Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.

NVO : 96.64 (-0.18%)
LLY : 598.05 (+1.66%)
PFE : 28.78 (+0.52%)
RHHBY : 36.0000 (+1.18%)
CRSP : 64.54 (-8.08%)
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?

Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.

NVO : 96.64 (-0.18%)
LLY : 598.05 (+1.66%)
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?

Novo Nordisk stock has been a red-hot buy this year -- can it continue that trend through this decade?

LLY : 598.05 (+1.66%)
NVO : 96.64 (-0.18%)
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?

Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy.

LLY : 598.05 (+1.66%)
NVO : 96.64 (-0.18%)
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?

Real-world data showed some real-world advantages for Ozempic's top rival.

NVO : 96.64 (-0.18%)
LLY : 598.05 (+1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 97.90
2nd Resistance Point 97.47
1st Resistance Point 97.06
Last Price 96.64
1st Support Level 96.22
2nd Support Level 95.79
3rd Support Level 95.38

See More

52-Week High 105.69
Last Price 96.64
Fibonacci 61.8% 89.93
Fibonacci 50% 85.07
Fibonacci 38.2% 80.20
52-Week Low 64.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar